Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP378942.RA-67NxUbLPArHQqijY7D1LS2jORQQ8Bp-82Xaf0IpxK8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP378942.RA-67NxUbLPArHQqijY7D1LS2jORQQ8Bp-82Xaf0IpxK8130_assertion type Assertion NP378942.RA-67NxUbLPArHQqijY7D1LS2jORQQ8Bp-82Xaf0IpxK8130_head.
- NP378942.RA-67NxUbLPArHQqijY7D1LS2jORQQ8Bp-82Xaf0IpxK8130_assertion description "[Collectively, these findings show that GBM therapeutic resistance to EGFR inhibitors may be explained by compensatory activation of EGFR-related family members (ERBB2, ERBB3) enabling GBM CSC proliferation, and therefore simultaneous blockade of multiple ERBB family members may be required for more efficacious GBM therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP378942.RA-67NxUbLPArHQqijY7D1LS2jORQQ8Bp-82Xaf0IpxK8130_provenance.
- NP378942.RA-67NxUbLPArHQqijY7D1LS2jORQQ8Bp-82Xaf0IpxK8130_assertion evidence source_evidence_literature NP378942.RA-67NxUbLPArHQqijY7D1LS2jORQQ8Bp-82Xaf0IpxK8130_provenance.
- NP378942.RA-67NxUbLPArHQqijY7D1LS2jORQQ8Bp-82Xaf0IpxK8130_assertion SIO_000772 22745588 NP378942.RA-67NxUbLPArHQqijY7D1LS2jORQQ8Bp-82Xaf0IpxK8130_provenance.
- NP378942.RA-67NxUbLPArHQqijY7D1LS2jORQQ8Bp-82Xaf0IpxK8130_assertion wasDerivedFrom befree-20150227 NP378942.RA-67NxUbLPArHQqijY7D1LS2jORQQ8Bp-82Xaf0IpxK8130_provenance.
- NP378942.RA-67NxUbLPArHQqijY7D1LS2jORQQ8Bp-82Xaf0IpxK8130_assertion wasGeneratedBy ECO_0000203 NP378942.RA-67NxUbLPArHQqijY7D1LS2jORQQ8Bp-82Xaf0IpxK8130_provenance.